Background The surgical treatment of stage I and II non-small cell lung cancer (NSCLC)
continues to evolve in the areas of intraoperative lymph node staging (specifically the issue …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Objectives: The non-small cell lung cancer (NSCLC) meta-analysis suggested a survival
benefit for cisplatin-based chemotherapy when given in addition to surgery, radical …

Study objectives Stage IIIA non-small cell lung cancer represents a relatively heterogeneous
group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant
therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an …

Radical surgery is the standard of care for fit stage I non-small cell lung cancer (NSCLC)
patients. Adjuvant treatment should be offered only as part of an investigation trial. Stage II …

Background. Nonsmall cell lung cancer (NSCLC) has become the leading cause of cancer‐
related deaths in women and men in the United States, with more than 157,000 estimated …

Background: Surgery is considered the treatment of choice for patients with resectable stage
I and II (and some patients with stage IIIA) non-small cell lung cancer (NSCLC), but there …